Home › Funds › Paradigm Biocapital Advisors LP › PCVX
Paradigm Biocapital Advisors LP position in PCVX
VAXCYTE INC · Health Care
Paradigm Biocapital Advisors LP reported holding 2,127,852 shares of PCVX (VAXCYTE INC) in its Q2 2026 13F filing — a position valued at US$123.7M, representing 2.32% of its reported portfolio and ranking #15 among its reported holdings. Paradigm Biocapital Advisors LP has disclosed PCVX holdings in 10 of the last 10 reported quarters, going back to Q1 2024.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Paradigm Biocapital Advisors LP's PCVX position evolved
Paradigm Biocapital Advisors LP first disclosed a stake in PCVX in Q1 2024 at 1,239,995 shares (US$84.7M). The position peaked in Q1 2026 at 4,793,020 shares, worth US$278.5M. Across 10 filings, Paradigm Biocapital Advisors LP increased the stake 6 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 2,127,852 shares valued at US$123.7M — a reduction of -2,665,168 shares quarter over quarter.. Notable position changes include a 56% trim in Q3 2024 (shares fell 28% over the following quarter), a 414% increase in Q4 2024 (shares fell 54% over the following quarter), a 99% increase in Q2 2025 (shares rose 11% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2024 | 1.24M | $84.70M | New |
| Q2 2024 | 627.20K | $47.36M | Reduce |
| Q3 2024 | 276.80K | $31.63M | Reduce |
| Q4 2024 | 1.42M | $116.47M | Add |
| Q1 2025 | 1.70M | $64.06M | Add |
| Q2 2025 | 3.37M | $109.65M | Add |
| Q3 2025 | 3.78M | $136.33M | Add |
| Q4 2025 | 4.07M | $187.70M | Add |
| Q1 2026 | 4.79M | $278.52M | Add |
| Q2 2026 | 2.13M | $123.69M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About PCVX and 13F data
PCVX (VAXCYTE INC) is a Health Care company. 35 other funds we track also report a position in PCVX — the largest reported positions include Jupiter Topco LLC (US$1.04B), Janus Henderson Group (US$960.2M), T. Rowe Price Investment Management, Inc. (US$709.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding PCVX
- Jupiter Topco LLC 17.97M sh · $1.04B · Q2 2026
- Janus Henderson Group 16.58M sh · $960.23M · Q1 2026
- T. Rowe Price Investment Management, Inc. 12.21M sh · $709.62M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 11.47M sh · $667.02M · Q2 2026
- Deep Track Capital, LP 4.30M sh · $249.96M · Q2 2026
- Kynam Capital Management, LP 2.92M sh · $169.88M · Q2 2026
- Caligan Partners LP 2.19M sh · $127.23M · Q2 2026
- Bellevue Group AG 1.97M sh · $114.63M · Q2 2026
- Maverick Capital 1.61M sh · $93.78M · Q2 2026
- MAVERICK CAPITAL LTD 1.61M sh · $93.78M · Q2 2026
- Pivotal bioVenture Partners Investment Advisor LLC 1.43M sh · $82.86M · Q2 2026
- EVENTIDE ASSET MANAGEMENT, LLC 1.38M sh · $80.23M · Q2 2026
More on Paradigm Biocapital Advisors LP
FAQ
How long has Paradigm Biocapital Advisors LP held PCVX?
Paradigm Biocapital Advisors LP has disclosed PCVX holdings in 10 of the last 10 reported quarters, going back to Q1 2024.
What is Paradigm Biocapital Advisors LP's current position in PCVX?
As of Q2 2026, Paradigm Biocapital Advisors LP holds 2.13M shares of PCVX (VAXCYTE INC), valued at $123.69M, representing 2.32% of its reported portfolio and ranking #15.
Has Paradigm Biocapital Advisors LP been buying or selling PCVX?
In the latest 13F filing (Q2 2026), Paradigm Biocapital Advisors LP reduced its position in PCVX. The position peaked in Q1 2026 at 4.79M shares.
Which other funds hold PCVX?
Other major institutional holders of PCVX include Jupiter Topco LLC, Janus Henderson Group, T. Rowe Price Investment Management, Inc., among 35 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.